About Matching Medicines...

Classic diagnostics determine the nature of a disease but give little or no information on how patients will respond to treatment. PamGene’s Matching Medicine approach ultimately aims to provide medical oncologists with valuable additional data to create the best plan for a particular patient, guiding the selection of likely responders, and avoiding non-responders experiencing unnecessary side effects and lost time.

Patient:drug response data, known as a PamGene Index (PamInDx) patient profile, have the potential to provide valuable predictive information to facilitate the matching of a medicine to a specific patient prior to drug administration. PamGene’s ambition is for Matching Medicines™ to become part of routine clinical practice.

PamGene’s biomarker discovery and validation activities are ongoing and are important in realising the full potential of the Matching Medicines approach. Extensive biomarker discovery in preclinical and clinical settings, for a number of cancer types, is ongoing.

Validation of the Matching Medicines approach has been undertaken and is ongoing in pre-clinical model systems (cell lines and xenograph experiments) and in clinical settings (clinical research and retrospective testing of patient samples matched to known data). A programme of clinical trials is underway to fully validate the Matching Medicines approach. PamGene’s Matching Medicines technology is being used by the pharmaceutical industry.